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Introduction: Surgery is essential to any curative plan for lung can-
cer, but is associated with a high complication rate. We sought to 
determine the impact of complications on long-term survival after a 
curative surgery for lung cancer, independent of the effect on early 
postoperative mortality.
Methods: We studied a population-based cohort of patients with 
lung cancer who underwent curative-intent surgery in the province of 
Quebec, Canada, from 2000 to 2005. Kaplan-Meier survival analysis 
was used to compare unadjusted overall survival (OS) beyond post-
operative day 90 for patients with and without complications. Cox 
regression was used to determine the prognostic impact of 30-day 
postoperative complications on the OS after adjusting for several 
confounders.
Results: The overall 30-day postoperative complication rate was 
58.2% among 4033 eligible patients. A major infectious compli-
cation (pneumonia, empyema, or mediastinitis) occurred in 378 
patients. The 5-year OS was lower for those with any postoperative 
complication (62.8%) than those without (73.8%; p < 0.001). Those 
with major infectious complications had the lowest OS (56.3%; 
p < 0.001). Postoperative complication was an independent prog-
nostic factor after adjusting for several patient and treatment factors 
(hazard ratio = 1.37; 95% confidence interval, 1.21–1.54). Adjusted 
hazard ratio for major infectious complications was 1.67 (95% con-
fidence interval, 1.39–2.01).
Conclusions: Postoperative complications, particularly of a major 
infectious type, are strong negative predictors of long-term survival 
in lung cancer patients. The strong association between major infec-
tious complications and survival may also open the door to inves-
tigational therapies targeting bacterial antigens in the perioperative 
period in patients who undergo lung cancer surgery.
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Worldwide, lung cancer is the most common cause of cancer-related death among males and the second 
cause in females.1 It is a major health problem in developed 
countries and in North America.1 Non–small cell lung cancer 
(NSCLC) accounts for approximately 85% of lung malig-
nancies, for which surgery remains the cornerstone of any 
potential cure.2 However, lung surgery is highly invasive with 
a 30-day operative mortality of 1.3% to 3.2% and a high post-
operative complication rate (25–40%), which are mainly pul-
monary in origin.3–5
Recent studies have shown poor long-term prognosis 
following postoperative complications for cancers of the 
colon,6 head and neck,7 liver,8 and esophagus.9 Although 
early mortality is increased in patients suffering from post-
operative complications, there is mounting evidence sug-
gesting that the systemic inflammatory consequences of 
postoperative complications may have a secondary deleteri-
ous influence on survival by increasing the risk of cancer 
recurrence.10,11 Furthermore, it has recently been demon-
strated that bacterial antigens, frequently encountered in 
postoperative infectious complications, have a direct effect 
on cancer cell metastatic ability.12,13
Although the experimental data linking systemic 
inflammation to cancer progression is compelling, the clini-
cal data in support of this notion are controversial and almost 
exclusively from retrospective, single institution surgical 
series or specialized cancer centers that either focus on the 
effect of complications on the early postoperative course or 
do not exclude patients who died in the immediate postop-
erative period when evaluating long-term survival.3–5 This is 
important to note, because postoperative morbidity increases 
operative mortality,4 and any potential impact of complica-
tions on cancer progression, will be overshadowed by short-
term increased mortality.
We thus sought to determine the impact of the 
postoperative complications on the long-term survival 
of patients undergoing a curative-intent surgery for lung 
cancer, independent of their impact on early postoperative 
mortality.
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PATIENTS AND METHODS
Data Collection and Study Cohort
This population-based retrospective cohort study was 
based on the linkage of administrative health care data from 
the province of Quebec, Canada, which has the highest inci-
dence and mortality rates for lung cancer in the country.14 
Information on survival and prognostic factors was gathered 
from the two main provincial health care databases: the Régie 
de l’Assurance Maladie du Québec (RAMQ) and the Ministry 
of Health’s Maintenance et Exploitation des Données pour 
l’Étude de la Clientèle Hospitalière (MED-ECHO). RAMQ 
serves as the government-managed health care insurer for 
all hospitalization and physician costs for more than 99% of 
residents in the province of Quebec.15 The MED-ECHO data-
base contains hospitalization records with data on all hospital 
admissions. We collected medical acts and diagnoses from 
before 4 years up to 1 year after the index date of lung sur-
gery. Outcome data on all-cause mortality was obtained up to 
5 years post index surgery date.
We identified all patients aged 18 and older who 
 underwent lung surgery in the province of Quebec, 
Canada from January 1, 2000 to December 31, 2004. The 
International Classification of Diseases, Ninth Revision-
Clinical Modification (ICD9-CM) diagnosis codes for lung 
cancer (162.3–5; 162.8–9) were used to identify subjects 
who had the index lung surgery for lung cancer from both 
the RAMQ and the MED-ECHO datasets. Data from both 
databases were linked using an encrypted 10-digit number 
as a unique identifier for each subject. Duplicate entries were 
eliminated. From this cohort, we excluded subjects with any 
metastatic disease (including that in lymph nodes) before or 
on the date of index surgery based on ICD9-CM diagnosis 
codes. We also excluded patients with a previous oncologic 
resection for lung cancer or reoperation beyond 30 days after 
the index surgery. Using these two criteria, we identified all 
patients who underwent lung cancer surgery with curative 
intent. Finally, patients who died before postoperative day 
(POD) 90 were excluded (Fig. 1).
We studied three complication-related prognostic vari-
ables: (1) any postoperative complication, (2) pulmonary 
versus nonpulmonary complications each containing both 
infectious and noninfectious morbidities, and (3) major 
infectious versus minor infectious versus noninfectious com-
plications. Pneumonia, empyema, and mediastinitis were 
considered to be major infections and other types were clas-
sified as minor (e.g., wound and urinary tract infections). 
Occurrence of postoperative complications was considered 
until POD30. All complications were identified by matching 
ICD9-CM codes from both administrative datasets. Regarding 
pneumonia, all the respective ICD9-CM codes corresponding 
to a nonviral cause until POD30 were included. The primary 
outcome was the 5-year overall survival (OS) defined as all-
cause mortality beyond POD90 from the index surgery.
The study proposal was approved by the Institutional 
Review Board of McGill University. Use of de-identified 
population health data from RAMQ and MED-ECHO 
databases was approved by the Comission d’Accès à  
l’ Information du Québec.
Statistical Analysis
Kaplan-Meier survival analyses were used to depict the 
OS for the entire study cohort from the date of index surgery 
and also with POD90 as starting point. Cumulative survival dis-
tributions based on the occurrence and types of complication 
were compared by log-rank tests. Prognostic impact of post-
operative complications was also examined using Cox propor-
tional hazards models. Follow-up time was considered from 
POD90 for time-to-event analysis. To determine the outcome 
status, we considered patients who continued to be RAMQ 
beneficiaries throughout the 60-month period of observation. 
Hazard ratios (HR) (and 95% confidence intervals [CI]) were 
used as a measure of the magnitude of association.
We controlled for several known confounders chosen 
a priori such as age, sex, socioeconomic status (education, 
income, and area of residence), comorbidities (compiled as 
Charlson comorbidity index [CCI]), neo/adjuvant therapy, 
30-day reoperations, and surgeon’s experience (Model I). 
Variables were categorized in three levels to permit assess-
ment of a dose-prognosis relationship. We also derived a 
second model (Model II) that included only empirical con-
founders of the relation between complications and survival, 
which were chosen in a stepwise fashion using a 2% change-
in-estimate rule in either direction for the target HR.16
Statistical analysis was carried out using STATA 
software (Stata Corp., College Station, TX) version 11. 
Inference was based on a two-sided 5% level.
RESULTS
A cohort of 9169 patients was identified encompassing 
all patients aged 18 and older who underwent a lung surgery 
FIGURE 1.  Definition of the study cohort. ICD9-CM, 
International Classification of Diseases, Ninth Revision-Clinical 
Modification; POD, postoperative day.
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in the province of Quebec, Canada, from 2000 to 2005 (Fig. 
1). Of these, 8060 patients underwent lung cancer surgery. We 
excluded from this subcohort 3656 patients with ICD9-CM 
codes corresponding to any metastatic disease (including 
that in lymph nodes) before or by the index surgery date, 
50 patients with a previous lung surgery more than 30 days 
before, and 65 patients with a repeat resection beyond 30 days 
past the index operation, as well as 256 subjects who did not 
survive beyond POD90. The final study cohort consisted of 
4033 eligible patients who underwent a potentially curative 
lung resection for their lung cancer and survived at least until 
POD90 (Fig. 1).
Characteristics at baseline for the study cohort are 
shown in Table 1. The overall 30-day postoperative compli-
cation rate was 58.2% (N = 2348) (Table 1). The different 
categories of complications were analyzed independently. 
Noninfectious complications were the most common (N = 
1550; 38.4%), followed by nonpulmonary (N = 1208; 29.9%). 
Infectious complications occurred in 798 patients and were 
further subdivided into two types: minor (e.g., wound infec-
tion and urinary tract infection; N = 420) and major (pneumo-
nia, empyema, and mediastinitis; N = 378). Atrial fibrillation 
was the most frequent of all complications (18%). Among 
the infectious complications, pneumonia was the most com-
mon (10.7%). The frequencies of different complications are 
listed in Table 2.
The cumulative 5-year OS for the study cohort was 
63.8% from the date of index surgery. Using POD90 as the 
starting point for the survival analyses, the OS was signifi-
cantly lower for those who had any postoperative complica-
tion (5-year OS: 62.8%) than for those without (5-year OS: 
73.8%) (p < 0.001; Fig. 2A). For patients with pulmonary and 
nonpulmonary complications the 5-year OS rates were 59.1% 
and 66.3%, respectively, both distributions being significantly 
lower than that for those without complications (p < 0.001; 
Fig. 2B). Among the patients with an infectious complica-
tion, those with a major infection had a significantly worse 
OS compared with those with minor infectious and nonin-
fectious complications (5-year OS: 56.3, 64.0, and 64.1%, 
respectively) (p < 0.001; Fig. 2C). All three survival distribu-
tions were again significantly lower than that for those without 
complications (p < 0.001; Fig. 2C).
These findings concerning differences in OS by pres-
ence and type of complications remained statistically signifi-
cant even if the starting time was chosen at POD30 or the date 
of index surgery (data not shown).
Multivariate Analysis
As Table 3 shows, Model I, after accounting for age, sex, 
income, education, area of residence (urbanicity), CCI, neo/
adjuvant therapy, 30-day reoperations, and surgeon’s years of 
experience, the mortality rate for those with any postopera-
tive complications was nearly 40% higher than for those with-
out complications (HR = 1.37, 95% CI: 1.21–1.54). Adjusted 
estimates for nonpulmonary and pulmonary complications 
were (HR = 1.21, 95% CI: 1.05–1.39; HR = 1.54, 95% CI: 
1.34–1.77), respectively. When classified based on occurrence 
and intensity of infections, patients with major infectious 
complications had the highest relative mortality rate (HR = 
1.67, 95% CI: 1.39–2.01). The estimates for minor infections 
and noninfectious complications were (HR = 1.27, 95% CI: 
1.05–1.54; HR = 1.31, 95% CI: 1.15–1.50), respectively. The 
sociodemographic parameters (income, education, and urba-
nicity), 30-day reoperations, and years of experience of the 
surgeon were not found to be significant prognostic indicators 
of survival (Table 3).
Postoperative complications remained significantly 
associated with survival even after conservatively (2% 
change-in-estimate) controlling for empirical confounders 
(age, sex, CCI, neo/adjuvant therapy, and surgeon’s years of 
experience), as shown in Table 3, Model II (HR = 1.36, 95% 
CI: 1.20–1.53). All prognostic effect measures for differ-
ent types of complications were essentially unchanged from 
Model I to Model II.
DISCUSSION
We found that the death rate among patients who suf-
fered from any postoperative morbidity after a curative-intent 
lung cancer surgery was almost 40% higher than that for those 
with no complications up to POD30. This effect was more 
profound in patients in whom the complication was because of 
a major infection (pneumonia, empyema, and mediastinitis); 
their death rate was nearly 70% greater than for those with no 
complications. Such substantial prognostic effects persisted 
even after accounting for empirical confounders. This is the 
first study to assess the negative impact of major infectious 
complications, such as pneumonia, on long-term survival in 
lung cancer patients at a population level and beyond the early 
postoperative period (90 days).
To our knowledge, there has been only one study 
showing a decreased long-term survival beyond POD30 for 
patients with stage I NSCLC who had any complication.17 
The study used Surveillance Epidemiology and End Results 
(SEER) data that captures less than one third of population 
in the United States.18 The need to link with the Medicare 
database to improve completeness of data restricted their 
population to 65 years and older. Further restriction was 
made to include stage I disease patients that only underwent 
a lobectomy.
In addition to being a large province-wide study free of 
restrictions on the basis of age and disease burden, our inves-
tigation also demonstrated that postoperative morbidity not 
only influences early mortality, but its negative impact lingers 
beyond the early postoperative phase with a lasting influence 
on the 5-year survival in lung cancer patients undergoing sur-
gery. After controlling for several confounders postoperative 
complications, particularly those pulmonary in origin and 
of a major infectious type, there remained significant nega-
tive predictors of survival beyond POD90. The 90-day cut-
off was chosen arbitrarily but as a conservative threshold to 
focus only on the long-term association between postopera-
tive morbidity and survival. Our choice was also based on 
the evidence that immediate impact of postoperative morbid-
ity after pulmonary resections may exceed the conventional 
30-day period, thus supporting use of 90 days as the limit for 
early postoperative events.19
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The ultimate question is whether infectious complica-
tions negatively impact long-term oncologic outcome of lung 
cancer. Minor infections such as postoperative wound com-
plications have been linked to both local and systemic tumor 
recurrence in colorectal and breast cancers20,21 yet the literature 
on the influence of such infections on cancer recurrence espe-
cially lung malignancies is sparse and inconsistent. Although 
our study is not an etiologic one looking at the association 
between grades of infection and tumor recurrence, to our 
knowledge, it is the first study evaluating the dose-prognosis 
relationship between the degree of infection and cancer sur-
vival. Furthermore, noninfectious complications were found 
to have an equivalent negative impact on 5-year OS as minor 
infections. This influence from noninfectious morbidities is 
probably in large part because of pulmonary complications, 
which was found in our study (data not shown) and aforemen-
tioned study using SEER data.17 Nevertheless, the underlying 
mechanism for a negative impact of postoperative morbidity 
on survival could be because of a worse oncologic outcome 
associated with tumor recurrence either locally or at a distant 
site facilitated by inflammation and associated immunological 
phenomena10,11,22 or, in the case of infectious complications, 
through bacterial antigen-mediated processes.12,13 Alternatively, 
the detrimental effect of postoperative complications could be 
because of unmeasured confounders. Regardless of the mecha-
nism, these findings have clinical utility. Postoperative com-
plications particularly those that are more proinflammatory 
(such as major infections, e.g., pneumonia) may be a proxy 
for the prognostic effect from unmeasured factors and thus 
efforts should be made to minimize postoperative morbidity 
for improved prognosis beyond short-term survival.
Several patient, tumor, and therapeutic factors have 
been linked to greater postoperative morbidity in addition 
to being identified as predictors of survival in patients with 
early-stage NSCLC. Age, sex, CCI, socioeconomic status, 
tumor size, grade, histology, cancer stage, neo/adjuvant 
therapy, and access to a high-volume thoracic surgery center 
TABLE 1.  Overall Survival Rate at 5 Years According  
to Baseline Characteristics of the Study Cohort
Patient characteristics N (%)
5-year OS%  
(95% CI)
Age a
 <60 1522 (37.7) 78.4 (76.2, 80.4)
 60–69 1354 (33.6) 65.8 (63.2, 68.3)
 ≥70 1157 (28.7) 54.8 (51.9, 57.6)
Sex a
 Female 1808 (44.8) 73.8 (71.7, 75.7)
 Male 2225 (55.2) 62.2 (60.1, 64.2)
Incomeb
 High (>$50,830) 1370 (34.0) 69.2 (66.7, 71.6)
 Middle 1332 (33.0) 67.1 (64.5, 69.6)
 Low (<$38,180) 1331 (33.0) 65.8 (63.2, 68.3)
Educationc a
 High (≤26% without  
 high school diploma)
1356 (33.6) 70.4 (67.9, 72.8)
 Middle 1411 (35.0) 65.8 (63.2, 68.2)
 Low (≥40% without  
 high school diploma)
1266 (31.4) 65.9 (63.3, 68.5)
Urbanicity
 Urban 2304 (57.1) 67.6 (65.6, 69.4)
 Suburban 1089 (27.0) 67.2 (64.3, 69.9)
 Rural/remote 633 (15.7) 67.1 (63.3, 70.6)
 Missing 7 (0.2) –
Charlson comorbidity index a
 0 1700 (42.1) 72.4 (70.2, 74.5)
 1 1140 (28.3) 68.3 (65.5, 70.9)
 2 676 (16.8) 62.6 (58.8, 66.1)
 ≥3 517 (12.8) 55.1 (50.7, 59.3)
Neo/adjuvant therapy a
 None 3555 (88.2) 70.3 (68.8, 71.8)
 ≤3 months pre/post surgery 227 (5.6) 52.0 (45.3, 58.2)
 >3 months pre/post surgery 251 (6.2) 39.4 (33.4, 45.4)
Reoperations in less than 30 days
 No 3917 (97.1) 67.6 (66.1, 69.0)
 Yes 116 (2.9) 60.3 (50.8, 68.6)
Surgeon’s experience, yr
 ≥20 2,297 (57.0) 66.3 (64.3, 68.2)
 16–20 874 (21.7) 70.2 (67.1, 73.2)
 10–15 244 (6.0) 66.4 (60.1, 71.9)
 <10 449 (11.1) 70.2 (65.7, 74.2)
 Missing 169 (4.2) –
Type of procedure a
 Pneumonectomy 137 (3.4) 51.8 (43.2, 59.8)
 Lobectomy 2329 (57.7) 66.2 (64.3, 68.1)
 Wedge and segmentectomy 605 (15.0) 72.7 (69.0, 76.1)
 Other 193 (4.8) 47.7 (40.5, 54.5)
 Missing 769 (19.1) –
Postoperative complications d
 No 1685 (41.8) 73.8 (71.6, 75.8)
 Yes 2348 (58.2) 62.8 (60.8, 64.7)
(Continued)
TABLE 1. (Continued)
Patient characteristics N (%)
5-year OS%  
(95% CI)
Type of complicatione d
 Noninfectious 1550 (38.4) 64.1 (61.6, 66.4)
 Minor infectious 420 (10.4) 64.0 (59.3, 68.4)
 Major infectiousf 378 (9.4) 56.3 (51.2, 61.2)
 Nonpulmonaryg 1208 (29.9) 66.3 (63.6, 68.9)
 Pulmonaryg 1140 (28.3) 59.1 (56.2, 61.9)
CI, confidence interval; OS, overall survival.
aLog-rank test within each category; p is less than 0.05. bAverage household income 
in the 6-digit postal code area of residence of each patient was estimated from Statistics 
Canada’s 2001 censuses data and divided into tertiles. cEducational level was approximated 
from Statistics Canada’s 2001 censuses data using the proportion of people without a 
high school certificate in the 6-digit postal code area of residence of each patient, and 
divided into tertiles. dLog-rank test compared with patients no complications; p is less 
than 0.001. ePatients may have more than one type of complication, but the categories 
were analyzed independently. f Major infectious complications were considered to be: 
pneumonia, empyema, and mediastinitis. gThe system-based complication categories 
include both infectious and noninfectious morbidities.
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are among the recognized confounders.23–25 We were not able 
to control for all these variables because of the limitations 
in using the provincial administrative health care databases 
that are primarily constructed for remuneration purposes. 
Nevertheless, our results confirmed age, sex, CCI, and neo/
adjuvant therapy as negative predictors with all showing 
dose-prognosis relationships. Lower socioeconomic sta-
tus was not found to be significantly associated with poor 
survival. This finding is likely because of universal access 
to health care for patients in Canada regardless of income, 
education, race, or area of residence. Similar results have 
been demonstrated in the United Kingdom, where a univer-
sal health care system is also in place.26 Experience of the 
treating surgeon, as measured by years of practice, was used 
as a proxy for the volume of lung surgeries performed by 
the surgeon, and found not to be an independent predictor of 
survival. This finding likely demonstrates that years of expe-
rience does not necessarily translate into proficiency in lung 
cancer surgery, instead it is the volume of surgical proce-
dures that has been associated with improved outcome after 
lung cancer surgery.27
Recently the National Surgical Quality Improvement 
Program which is a risk-adjusted data collection mechanism 
designed to help participating hospitals develop quality initia-
tives and improve surgical care, is becoming the gold standard 
for looking at postoperative morbidities.28 However, even 
National Surgical Quality Improvement Program has limita-
tions, as it may not represent all hospitals across the United 
States (approximately 350 participating centers as of 2011) 
and its figures regarding surgical morbidities may be under 
or overestimated especially without regard to surgical site, 
indication for surgery, and procedure performed as recently 
shown for breast cancer surgery.29
Thirty-day postoperative complications occurred at a 
high rate of 58% in our study cohort, which is higher than 
what has been reported.3,5 However, most studies were based 
on voluntary reporting sources or on patients treated in single 
institutions or specialized cancer centers. We identified post-
operative complications from the provincial databases using 
specific ICD9-CM diagnosis codes. Therefore, the estimated 
incidence rate of 30-day complications represents docu-
mented outcome events for the entire population in the prov-
ince of Quebec and a more realistic estimate of what happens 
at provincial or even national level given that a large pro-
portion of lung cancer surgery is performed by nonthoracic 
surgeons that may lead to inferior outcomes.30 The complica-
tion rate for this Quebec study was comparable with that of 
the aforementioned study using SEER data (54%).17 Thirty-
day mortality rate in our study cohort was 3.6%, which is 
somewhat higher than expected (1.3%–3.2%).4,5 Inclusion of 
more advanced cases in the study cohort could explain the 
observed estimate.
Certain factors need to be taken into consideration 
when interpreting our findings. Currently accepted 5-year 
survival for stage I NSCLC after a curative surgery with or 
TABLE 2.  Distribution of Postoperative Complications 
Among Lung Cancer Patients
Complication type  
(N = 2348) Category N (%)a
Pulmonary
Atelectasis 338 (14.4)
ARDS and respiratory failure 267 (11.4)
Pneumoniab 251 (10.7)
Empyemab 135 (5.7)
Pulmonary embolism 124 (5.3)
Pulmonary edema 73 (3.1)
Chylothorax 10 (0.4)
Mediastinitisb 7 (0.3)
Unspecified 245 (10.4)
Nonpulmonary
Atrial fibrillation 422 (18.0)
Urinary tract infectionc 338 (14.4)
Heart failure and cardiac arrest 301 (12.8)
Wound infectionc 131 (5.6)
Hemorrhage 128 (5.4)
Renal complications 49 (2.1)
Wound dehiscence 30 (1.3)
Shock 16 (0.7)
Neurological complications 8 (0.3)
Unspecified 866 (36.9)
ARDS, acute respiratory distress syndrome.
aThe frequencies do not add up to the total number of complications because each 
patient may have more than one postoperative complication. bPneumonia, empyema, and 
mediastinitis were considered major infectious complications. cWound and urinary tract 
infections are considered minor infectious complications.
FIGURE 2.  Cumulative survival experience according to 
type of postoperative complication. (A) Presence of any post-
operative complication: (dashed black line) versus no com-
plications (solid black line). (B) Pulmonary (red line) versus 
nonpulmonary complications (blue line) (no complications: 
solid black line). (C) Infectious complications: major infectious 
(green line), minor infectious (maroon line), noninfectious 
(navy line), and no complications (solid black line). Survival 
distributions by Kaplan–Meier method. POD90, postoperative 
day 90.
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TABLE 3.  Multivariable Predictors of Survival After Curative-Intent Surgery for Lung 
Cancer
Model Ia Model IIb
Predictors HR (95% CI) HR (95% CI)
Age
 < 60 Reference Reference
 60–69 1.54 (1.33, 1.78) 1.55 (1.33, 1.79)
 ≥70 2.03 (1.76, 2.36) 2.04 (1.76, 2.37)
Sex
 Female Reference Reference
 Male 1.35 (1.20, 1.52) 1.35 (1.20, 1.52)
Income
 High Reference
 Middle 1.00 (0.85, 1.15)
 Low 1.07 (0.92, 1.25)
Education
 High Reference
 Middle 1.10 (0.95, 1.27)
 Low 1.08 (0.92, 1.27)
Urbanicity
 Urban Reference
 Suburban 1.05 (0.92, 1.20)
 Rural/remote 0.97 (0.82, 1.15)
Charlson comorbidity index
 0 Reference Reference
 1 1.12 (0.97, 1.29) 1.12 (0.97, 1.29)
 2 1.20 (1.02, 1.41) 1.21 (1.03, 1.41)
 ≥3 1.38 (1.17, 1.63) 1.38 (1.17, 1.62)
Neo/adjuvant therapy
 None Reference Reference
 ≤3 months pre/post surgery 1.85 (1.47, 2.29) 1.89 (1.52, 2.34)
 >3 months pre/post surgery 2.64 (2.21, 3.15) 2.64 (2.21, 3.16)
Reoperations in less than 30 days
 No Reference
 Yes 1.34 (0.90, 2.00)
Surgeon’s experience, yr
 ≥20 Reference Reference
 16–20 0.86 (0.74, 1.00) 0.85 (0.74, 1.00)
 10–15 0.96 (0.76, 1.21) 0.96 (0.77, 1.21)
 <10 0.82 (0.68, 1.00) 0.83 (0.69, 1.00)
Postoperative complications
 Noc Reference Reference
 Yes 1.37 (1.21, 1.54) 1.36 (1.20, 1.53)
Type of complicationd
 Noninfectious 1.31 (1.15, 1.50) 1.30 (1.14, 1.49)
 Minor infectious 1.27 (1.05, 1.54) 1.27 (1.05, 1.54)
 Major infectiouse 1.67 (1.39, 2.01) 1.66 (1.38, 2.00)
 Nonpulmonary 1.21 (1.05, 1.39) 1.20 (1.04, 1.38)
 Pulmonary 1.54 (1.34, 1.77) 1.53 (1.34, 1.75)
CI, confidence interval; HR, hazard ratio. 
aModel I is the full model that includes all the a priori chosen confounders. bModel II is based on empirical 
confounders that exerted a minimum of a 2% change in the estimates of the main exposure variables. cThe category 
of patients without any postoperative complications is the fixed reference group for all the categories pertaining to the 
different types of complications. dPatients may have more than one type of complication, but the categories are analyzed 
independently. eMajor infectious complications are considered to be: pneumonia, empyema, and mediastinitis.
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without combination therapy varies from 51% to 83%, and 
for stage II ranges from 30% to 60%.24,31 However a com-
mon limitation to using a provincial administrative health 
care database is that it does not include cancer-specific data 
such as cancer type and stage, tumor size, grade, and histol-
ogy, which prevented us from conducting stratified analyses 
on these characteristics. Regarding histology, NSCLC is the 
predominant histological subtype of lung cancer amenable 
to surgery (carcinoids represent less than 1%–2% in most 
surgical series)32 and small-cell lung cancer is highly inva-
sive with a poor 5-year OS of less than 10%.33 Hence, we are 
confident that the vast majority of patients in our cohort had 
NSCLC. To further counter this bias, and select only those 
patients with an early stage disease amenable to a curative 
resection, we implemented conservative exclusion criteria, 
which even excluded some patients with stages IIA, IIB, 
and IIIA with node-positive disease, who were still candi-
dates for curative-intent surgery. We felt that this conserva-
tive approach was necessary to allow us to assess the impact 
of postoperative complications on long-term survival only 
in those patients with the best chance for both cure and 
long-term survival, even though this restriction may have 
decreased the generalizability of the results (to all curative-
intent surgeries). Furthermore, the 5-year OS of our study 
cohort was within the accepted survival range for patients 
with stages I and II NSCLC, who have undergone a curative 
resection and is also comparable with that of the aforemen-
tioned SEER study17 that demonstrates external validity and 
consistency of our findings.
Another limitation was our inability to calculate cancer-
specific survival because the administrative health care data 
provided us only with all-cause mortality. That said, overall 
mortality is a commonly used outcome in population-based 
cancer survival studies.34 Despite its limitations, our study has 
several strengths, such as a large sample size, broad popula-
tion base, and use of province-wide administrative data that 
capture virtually all health care procedures for the population, 
thus improving generalizability of the findings.
In practical terms, our findings demonstrate the negative 
potential impact of postoperative complications on long-term 
oncologic outcomes in lung cancer patients. These findings 
may help identify important targets for a combination of peri-
operative preventive strategies such as fast-track surgery and 
multidisciplinary protocols with an aim to decrease postop-
erative morbidity especially major infections such as pneu-
monia that have been shown to be effective in other types of 
surgeries, such as intestinal resections.35,36 Furthermore, the 
strong association between major infectious complications 
and survival may open the door to investigational therapies 
targeting bacterial antigens in the perioperative period in 
patients undergoing lung cancer surgery.
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